New Vaccine-Drug combo aims to tame HPV throat cancer with less radiation
NCT ID NCT07628062
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment plan for people with HPV-positive oropharyngeal cancer (a type of throat cancer linked to HPV). The plan combines an immune-boosting drug (nogapendekin alfa inbakicept), a vaccine targeting HPV, chemotherapy, and a lower dose of radiation. The goal is to see if this approach is safe and works better than the standard treatment, while possibly reducing long-term side effects from radiation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nogapendekin alfa inbakicept, hAd5-HPV vaccine, nab-paclitaxel, cisplatin, and de-intensified radiation
What this could lead to
If successful, this approach could offer a more effective and less toxic treatment option for people with HPV-positive oropharyngeal cancer, potentially reducing the need for high-dose radiation.
What could go wrong
This is a Phase 2 trial, so the treatment is still experimental. It may not prove more effective than standard care, and there are risks of side effects from the drugs and radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.